share_log

6-K: Novo Nordisk Stops the Ocedurenone CLARION-CKD Trial and Recognises Impairment Loss

6-K: Novo Nordisk Stops the Ocedurenone CLARION-CKD Trial and Recognises Impairment Loss

6-K:諾和諾德停止Ocedurenone CLARION-CKD試驗並確認減值損失
美股SEC公告 ·  06/26 13:22

Moomoo AI 已提取核心訊息

On June 26, 2024, Novo Nordisk A/S, a leading global healthcare company, announced the termination of the CLARION-CKD phase 3 trial, which was evaluating ocedurenone in patients with uncontrolled hypertension and advanced chronic kidney disease. The decision to stop the trial came after an independent data monitoring committee concluded that the trial did not meet its primary endpoint during a prespecified interim analysis. As a result, Novo Nordisk will recognize an impairment loss of approximately DKK 5.7 billion, which is expected to negatively impact operating profit growth by about 6 percentage points for the year 2024. This financial impact is in comparison to the operating profit outlook previously communicated for the first quarter of 2024. The company, which acquired ocedurenone from KBP Biosciences PTE., Ltd. in 2023, is now evaluating the further development of ocedurenone for other indications. Novo Nordisk will disclose its financial results for the first half of 2024 and update its financial outlook for the full year on August 7, 2024.
On June 26, 2024, Novo Nordisk A/S, a leading global healthcare company, announced the termination of the CLARION-CKD phase 3 trial, which was evaluating ocedurenone in patients with uncontrolled hypertension and advanced chronic kidney disease. The decision to stop the trial came after an independent data monitoring committee concluded that the trial did not meet its primary endpoint during a prespecified interim analysis. As a result, Novo Nordisk will recognize an impairment loss of approximately DKK 5.7 billion, which is expected to negatively impact operating profit growth by about 6 percentage points for the year 2024. This financial impact is in comparison to the operating profit outlook previously communicated for the first quarter of 2024. The company, which acquired ocedurenone from KBP Biosciences PTE., Ltd. in 2023, is now evaluating the further development of ocedurenone for other indications. Novo Nordisk will disclose its financial results for the first half of 2024 and update its financial outlook for the full year on August 7, 2024.
2024年6月26日,全球領先的醫療保健公司諾和諾德宣佈終止評估未控制的高血壓和晚期慢性腎臟病患者的o文章的III期CLARION-CKD試驗。停止試驗的決定是在預定中期分析期間,由一家獨立的數據監控委員會得出該試驗未達到其主要終點的結論。因此,諾和諾德將確認大約57億丹麥克朗的減值損失,預計將對2024年營業利潤增長產生約6個百分點的負面影響。這種財務影響與此前已發佈的2024年第一季度營業利潤前景相比。該公司於2023年從KBP Biosciences PTE.,Ltd.獲得了o文章,現正在評估o文章在其他適應症方面的進一步發展。諾和諾德將在2024年8月7日披露其2024年上半年的財務業績並更新全年的財務前景。
2024年6月26日,全球領先的醫療保健公司諾和諾德宣佈終止評估未控制的高血壓和晚期慢性腎臟病患者的o文章的III期CLARION-CKD試驗。停止試驗的決定是在預定中期分析期間,由一家獨立的數據監控委員會得出該試驗未達到其主要終點的結論。因此,諾和諾德將確認大約57億丹麥克朗的減值損失,預計將對2024年營業利潤增長產生約6個百分點的負面影響。這種財務影響與此前已發佈的2024年第一季度營業利潤前景相比。該公司於2023年從KBP Biosciences PTE.,Ltd.獲得了o文章,現正在評估o文章在其他適應症方面的進一步發展。諾和諾德將在2024年8月7日披露其2024年上半年的財務業績並更新全年的財務前景。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息